Summary of Key Points
Moderna's personalized tumor vaccine, Intismeran, has achieved success in Phase III clinical trials. When used in combination with PD-1 inhibitors, it significantly reduced the risk of melanoma recurrence after surgery, driving the company's stock price up by 138% in just one week. This vaccine is not designed for cancer prevention but rather for post-surgical patients. It utilizes mRNA technology to activate the immune system to prevent recurrence, and the cost is likely to be in the hundreds of thousands of dollars. Among Chinese companies, traditional vaccine manufacturers face high barriers to transformation, while smaller, unlisted firms (such as Anda Biotech and Likang Life) are making faster progress, although they may not see approval until around 2030. The industry believes this technology has demonstrated the therapeutic potential of mRNA, but further validation is needed across different types of tumors, and issues such as cost and scope of application remain to be addressed.
1. This “tumor vaccine” is not a “prevention shot”; it’s a “recurrence blocker” for post-surgery patients
Many people think of tumor vaccines as similar to HPV vaccines, which are given to healthy individuals to prevent cancer. However, Moderna's vaccine is intended for patients who have already had their tumors removed, with the goal of preventing cancer cells from returning. Here’s how it works:
- Personalization: The patient's tumor sample and blood are collected to identify unique “markers” (called neoantigens) on the tumor cells.
- AI screening: AI is used to select the 34 markers that are most likely to be recognized by the immune system.
- mRNA instruction: These markers are encoded into an mRNA vaccine, which is then administered to the patient to stimulate the production of these markers in their body cells.
- Immune activation: Once the immune system recognizes these markers, it learns to identify them as “bad actors,” and any remaining cancer cells will be precisely eliminated.
This vaccine works in conjunction with PD-1 inhibitors (such as Keytruda). PD-1 inhibitors act by “relaxing the brakes” on the immune system’s response to tumors, while the vaccine acts as a “gas pedal” and “navigation system” to guide immune cells to the tumor. In this trial, the combination reduced the recurrence risk by 49%, showing a clear improvement in effectiveness.
2. Moderna’s rise from obscurity to global prominence
Moderna’s success was not an overnight achievement:
- Early setbacks: Founded in 2010, the company initially focused on mRNA virus vaccines but faced consecutive failures, which left the team feeling discouraged.
- The COVID-19 breakthrough: The outbreak of the pandemic in 2020 provided an opportunity. Moderna developed an mRNA COVID-19 vaccine in just 63 days, proving the feasibility of the technology and generating significant revenue (US$19.2 billion in 2022).
- AI’s role: Advances in AI technology after COVID-19 helped accelerate the development of the tumor vaccine by facilitating the rapid screening of neoantigens.
- Right choice of target: Melanoma was chosen for the trial because it is highly responsive to immunotherapy and has many genetic mutations, making it an ideal candidate for this approach.
Moderna is now expanding its efforts beyond tumors to include influenza, rare diseases, and autoimmune disorders, showing great ambition.
3. Where are China’s “Modernas”?
The success of Moderna has attracted investors seeking Chinese counterparts:
- Secondary market excitement: Stocks of traditional vaccine companies like CanSino and Wantai Biotech soared but quickly declined, as they primarily produce generic vaccines that have not yet entered clinical trials.
- Barriers for traditional companies: Transforming into personalized tumor vaccine manufacturers requires three key capabilities:
1. AI for neoantigen screening (not necessary for generic vaccines).
2. Customized production processes for each patient.
3. Clinical experience with tumors and knowledge of how to combine with PD-1 inhibitors.
- Progress from smaller companies: Unlisted biotechs like Anda Biotech and Likang Life are making faster progress:
- Anda Biotech: Developing peptide-based personalized vaccines for pancreatic cancer, with Phase II trials underway.
- Likang Life: Using mRNA-DC technology for multiple solid tumors, with clinical trials in Leshan, Hainan.
- Approval expected by 2030: Even the fastest Chinese companies are still in Phase II; completing full clinical trials takes at least 5-6 years.
4. A bright future, but with challenges
Despite the potential, there are several issues:
- High cost: The cost of personalized vaccines could be in the hundreds of thousands of dollars per patient, making them unaffordable for most families.
- Limited scope of application: These vaccines are only suitable for patients without residual tumor tissue after surgery, not for those with advanced, metastatic cancer.
- Scope of tumor types: Success has been demonstrated only in melanoma; effectiveness in other cancers (such as lung and stomach cancer) is still uncertain.
- Trade-off between generality and personalization: Generic vaccines are cheaper but may be less effective, which is a topic of debate in the industry.
5. Industry impact: A ripple effect across the sector
Moderna’s success has energized the entire industry:
- Upstream and downstream benefits: Companies in gene sequencing, AI algorithms, and mRNA delivery technologies (such as LNP) will see opportunities.
- Industry improvement: There is pressure to optimize the production cycle and reduce costs of personalized vaccines.
- Regulatory changes: Previous experimental frameworks in places like Leshan, Hainan, need to be aligned with national regulations to clarify approval processes for personalized vaccines.
- International cooperation: Chinese small companies may collaborate with foreign pharmaceutical giants to globalize this technology.
In conclusion
Moderna’s success has opened new possibilities for cancer treatment, but it’s still a long way before personalized vaccines become widely available to the general public. Chinese patients will likely have to wait until around 2030, and the cost needs to be reduced. Nevertheless, this breakthrough offers new hope for a cure for cancer.
(End of translation)